Surface Oncology Inc

NASDAQ:SURF   3:59:00 PM EDT
7.71
-0.21 (-2.65%)
Products

Surface Oncology Says Co Entered Into An Exclusive Product License Agreement With Vaccinex, Inc.

Published: 05/03/2021 12:29 GMT
Surface Oncology Inc (SURF) - Surface Oncology Inc - on March 23, Entered Into an Exclusive Product License Agreement With Vaccinex, Inc.surface Oncology - Vaccinex Granted Co a Worldwide, Exclusive, Sublicensable License Covering Antibody Srf114 Targeting Ccr8.
Surface Oncology Inc - Co Paid Vaccinex a One-time Fee of $850,000.
Surface Oncology Inc - Vaccinex is Eligible to Receive Up to an Aggregate of $3.5 Million Based on Achievement of Certain Clinical Milestones.
Surface Oncology Inc - Vaccinex is Eligible to Receive Up to $11.5 Million Based on Achievement of Certain Regulatory Milestones per Licensed Product.